A baculovirus-expressed VP4 protein derived from the simian rhesus rotavirus (RRV) was used to parenterally immunize murine dams. VP4-immunized dams developed high levels of neutralizing antibodies against RRV and low levels of cross-reactive neutralizing antibodies against human strains Wa, ST3, and S2 and animal strains SA-ll, NCDV, and Eb. Newborn mice suckled on VP4-immunized dams were protected against a virulent challenge dose of the simian strain RRV and against murine rotavirus Eb. The cross-reactive nature of the serum-neutralizing response generated by VP4 immunization and the protective efficacy of the immunization suggest that recombinant-expressed VP4 proteins should be considered as viable vaccine candidates.
Rotaviruses are one of the leading causes of severe gastroenteritis in infants and young children throughout the world. In developing countries, rotavirus infection is also associated with a high rate of infant mortality. Estimates suggest that 5 x 105 to 1 x 106 deaths annually might be prevented by an effective rotavirus vaccine (4) .
Rotaviruses belong to the family Reoviridae and are composed of two capsid layers forming a 70-nm icosahedral virion (8, 13) . The rotavirus genome contains 11 doublestranded RNA segments which encode structural and nonstructural viral proteins (14 to 120 kilodaltons). The outer capsid is composed of two proteins, VP7 and VP4, in a 13:1 molar ratio (32) . VP7 is the viral glycoprotein (37 kilodaltons) which specifies the rotavirus serotype (3, 5, 10, 12, 16, 23) and is involved in viral neutralization (10, 12, 14, 16, 20, 24) . Gene segment 4 of rhesus rotavirus (RRV) encodes the nonglycosylated outer capsid protein VP4 (86.5 kilodaltons) (20) . VP4 is responsible for binding the erythrocyte protein glycophorin (19) and is the viral hemagglutinin (15, 19) . VP4 is cleaved by trypsin to VP8 and VP5 polypeptide components, resulting in enhanced viral infectivity (7) . VP4 has also been associated with viral virulence and penetration of the virion into the cell (9, 18, 25, 36, 37) .
Antibodies directed at VP4 inhibit viral hemagglutination and neutralize the virus in vitro (3, 12, 17, 19, 20, 24, 33, 35, 39) . Shaw et al. (33, 35) have mapped neutralization domains on the VP4 and VP7 proteins of RRV and demonstrated that serotype-specific and cross-reactive neutralization epitopes exist on both outer capsid proteins. We extended these studies by determining the amino acids involved in heterologous and homologous RRV neutralization by selecting a series of neutralizing monoclonal antibody (N-MAb)-resistant mutants and sequencing their VP4-or VP7-encoding gene segments (20, 21) . The results of the mutational analysis of gene 4 demonstrated that a cross-reactive neutralizing domain exists in VP5, along with several largely homotypic neutralization sites in VP8 (21) .
Passive-transfer studies have also been used to determine that both VP8-and VP5-specific N-MAbs are able to protect * Corresponding author. mice from virulent rotavirus challenge (22, 27, 30) . By using a passive murine challenge model (26, 28, 29) , Offit and Clark (26) (30) and Matsui et al. (22) found that N-MAbs specific for the VP8, VP5, and VP7 proteins could protect mice from rotavirus disease. The importance of the immune response to VP4 in humans has also been demonstrated. Eighty percent of the serum neutralizing-antibody activity in sera from infected adult volunteers appears to be directed toward the VP4 protein (40) , and in young children, antibodies to VP4 occur more frequently and at an earlier age than do VP7-specific antibodies (38) .
To directly evaluate the role of the VP4 protein in disease prevention, a system for obtaining the isolated VP4 protein was established by expressing the protein at high levels in a recombinant baculovirus (19) . Our previous findings demonstrated that both VP8-and VP5-specific neutralization sites are present on the expressed VP4 protein (19) . In fact, not only is the expressed VP4 protein functionally active in hemagglutinating erythrocytes, but it also contains a complete complement of antigenically conserved neutralization domains (19) . The stability of the neutralizing epitopes of the baculovirus-expressed VP4 protein suggest that immunization with expressed VP4 protein may elicit a protective immune response.
In this study we immunized dams with complete RRV VP4 protein expressed by a recombinant baculovirus. Suckling newborn mice were then challenged with the rhesus strain of simian rotavirus or the murine rotavirus strain Eb. VP4-immunized dams passively protected the newborns from either rotavirus challenge. These findings are discussed in terms of a recombinant rotavirus vaccine strategy.
MATERIALS AND METHODS
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a Hemagglutination inhibition (HI) titers are expressed as the reciprocal of the serum dilution required to inhibit hemagglutination of 4 to 8 hemagglutination units of RRV.
b Focus reduction neutralization (FRN) data represent the reciprocal of the serum dilution resulting in a 60% reduction in the number of infected MA104 cells.
rus. Prior to immunization, sera were assayed by immunoprecipitation of RRV proteins for the presence of preexisting antibodies to rotavirus (11) . Only seronegative dams were used in subsequent studies. Cells and virus. Rotaviruses were grown on a continuous line of MA104 monkey kidney cells as previously described (34) . Seed stocks of rotavirus strains with known titers were used as challenge virus or in focus reduction neutralization assays (33) . The animal viruses used were as follows: RRV (simian), serotype 3 (st3); SA-11 (simian), st3; Eb (murine), st3; Gottfried (porcine), st4; OSU (porcine), st5; and NCDV (bovine), st6. The following human strains were used: Wa stl; DS1, st2; S2, st2; Price, st3; and ST3, st4.
The VP4-expressing baculovirus recombinant was grown as previously described (19) on Spodoptera frugiperda Sf-9 cells in Excell 400 medium (JR Scientific, Woodland, Calif.).
Immunization. Seronegative female CD-1 mice were initially immunized intraperitoneally at 8 weeks of age with 5 ,ug of baculovirus-expressed VP4 protein as an Autographa californica nuclear polyhedrosis virus (AcNPV)-infectedcell sonic extract or control AcNPV-infected-cell sonic extract, as 50:50 mixtures in complete Freund adjuvant. Mice were boosted at 11 and 15 weeks with a 50:50 mixture of VP4 (5 jig, partially purified from AcNPV supernatants by DEAE-cellulose binding in 0.1 M NaCl and elution in 0.5 M NaCl) or AcNPV-infected-cell control protein in incomplete Freund adjuvant. Two females were bred with each CD-1 male at 15 weeks of age. Males were removed 2 weeks later, and dams delivered pups at 18 to 19 weeks of age. Dams were bled again 2 days after giving birth and immunized intraperitoneally with VP4 protein (5 ,ug, as assayed by a Coomassie blue staining band on polyacrylamide gel electrophoresis [19] ) or AcNPV control protein without adjuvant.
Rotavirus challenge of suckling mice. Control and VP4-immunized litters of 4-to 5-day old suckling mice were given oral RRV (4 x 107 PFU) or Eb rotavirus (1 x 104 focusforming units) in 0.1 ml through a gavage needle. Doses were chosen to cause diarrhea in .90% of inoculated animals.
Diarrheal disease was determined daily by gentle abdominal palpation (26, 30) .
Focus reduction neutralization and hemagglutination inhibition assays. An immunoperoxidase staining technique for detecting infected cells was used in a neutralization assay essentially as described previously (33 were collected after an additional 6-h incubation at 37°C (11) . Radiolabeled proteins were immunoprecipitated as previously described (11), with hyperimmune anti-RRV guinea pig serum, monoclonal antibodies to VP2 and VP6, or sera from VP4-immunized or control immunized mice. Proteins were resolved on 10% polyacrylamide gels, and bands were identified by fluorography of the dried gel.
RESULTS
As a first step in evaluating the efficacy of recombinant VP4 as a vaccine candidate, we sought to characterize the extent and specificity of the humoral immune response to this protein in mice. Dams were immunized parenterally with either the RRV VP4 expressed from a baculovirus recombinant or control wild-type AcNPV-infected-cell proteins. To be sure that the neutralizing activity detected in the immune sera was due exclusively to antibody to VP4, we tested these sera by immunoprecipitation, using a metabolically labeled rotavirus-infected cell lysate. Mice immunized with the recombinant VP4 protein developed serum antibody responses to VP4 that were capable of immunoprecipitating only the VP4 protein from RRV-infected cell lysates (Fig. 1) . The VP4 postimmunization sera did not contain antibodies which recognize VP6 and VP2 proteins, indicating that the mice had not previously been exposed to rotaviruses.
Dams immunized with RRV VP4 developed high levels of serum neutralizing and hemagglutination-inhibiting antibodies to the homologous RRV strain ( The serum from VP4-immunized animals was first analyzed for rotavirus-specific neutralizing antibodies. Our results demonstrate that VP4-immunized animals generate high-level serum neutralizing antibodies directed at the immunizing VP4 protein and low-level cross-reactive neutralizing antibodies toward a variety of rotaviruses with different VP4 proteins (Table 1) . VP4 is apparently highly immunogenic and induces both strain-specific and cross-reactive neutralizing antibodies in immunized animals. This suggests that epitopes on both the largely serotype-specific VP8 portion of VP4 and the cross-reactive VP5 portion of VP4 (21) are immunogenic as well as antigenic. Apparently RRV VP4 immunization does not induce a neutralizing-antibody response to all strains of rotavirus. In fact, cross-reactivity with the human strains studied was limited. To produce a response directed at human rotaviruses, the use of alternative VP4 proteins, the inclusion of several VP4 protein types, or the expression of truncated VP4 polypeptides involved in cross-reactive neutralization could be considered in future immunization schemes.
Neutralizing titers against viruses other than RRV appear to reflect the level of cross-reactive antibodies generated by VP4 immunization and also to define a lineage of related VP4 neutralizing epitopes on these diverse rotavirus strains. It appears that serotype 4 virus ST3 contains the most similarity with the RRV VP4 neutralization epitopes (Table 1) . Neutralizing-antibody responses to widely diverse rotavirus strains SA-11 (st3), NCDV (st6), and Wa (stl) are similar in titer and represent conserved VP4 epitopes with RRV. Immunization with the RRV VP4 also generated a low level of neutralizing antibody to Eb (st3), OSU (st5), and S2 (st2), whereas virtually no neutralizing-antibody response was observed to DS1 (st2), Price (st3), and Gottfried (st4) strains (Table 1) . On the basis of cross-reactive VP4 neutralization responses elicited by RRV VP4 immunization, the relationship of viral VP4s is RRV > ST3 > Wa, SA-11, NCDV > Eb, OSU, S2 > Gottfried, DS1, Price.
The model chosen to study the utility of VP4 in disease prevention is the murine passive protection model established by Offit et al. (26, 28, 29) . In this system, protection from rotavirus diarrhea relies on the passive transfer of protective colostral antibody from an immunized dam to suckling mice (26) . Colostral antibody from the mother rather than transplacentally transferred antibody protects pups from rotavirus diarrhea in this model, since mice born to rotavirus-immunized mothers are not protected when foster nursed on seronegative dams (26) .
In this study, dams were immunized with the expressed VP4 protein or control protein. Pups were delivered and challenged with either RRV or Eb 5 days after birth. VP4-immunized mothers completely or nearly completely protected pups from rotavirus disease due to RRV and Eb, respectively (Table 2) . Hence, VP4 immunization of dams is an effective method for providing protection from rotavirus strains with the same (RRV) or conserved (Eb) VP4 neutralization epitopes.
Protection from the Eb strain of rotavirus was surprising, since the serum neutralizing titers to Eb were low in the dams (Table 1) . However, a cross-reactive neutralizing epitope defined by MAb 2G4 (21, 33) recognizes both RRV and the Eb rotavirus strain, and serum from VP4-immunized dams contains antibody directed at the 2G4 epitope as assayed in a solid-phase competition assay. It is possible that conservation of this cross-reactive VP5 epitope (21) and perhaps others contributed to the protection of pups from the murine Eb rotavirus strain.
The Eb strain of murine rotavirus is highly infectious for suckling mice, undergoes multiple rounds of replication in the mouse intestine, and spreads efficiently among littermates. In this study, more than 1,000 50% diarrhea doses of the Eb virus were administered as a challenge, and suckling pups from dams immunized with VP4 were protected. In trying to further characterize the nature of protection induced by the passive transfer of antibody from the mothers, we examined the sera of the pups following Eb challenge. Although the pups were protected from Eb challenge, the 
